Skip to main content

Table 1 Patients’ characteristics

From: IL32 expression in peripheral blood CD3+ cells from myelodysplastic syndromes patients

Patients Number
MDS 39
 Gender
  Male/Female 18/21
Age (years), median (range): 69 (27–89)
 WHO classification  
  RA/RARS/RCMD 04/07/20
  RAEB-1/RAEB-2 07/01
Cytogenetic riska
 Very good/good 01/32
 Intermediate 02
 Poor/very poor 01/01
 No growth 02
  1. Abbreviations: MDS myelodysplastic syndromes, WHO World Health Organization, RA refractory anemia, RARS refractory anemia with ringed sideroblasts, RCMD refractory cytopenia with multilineage dysplasia, RAEB-1 refractory anemia with excess blast-1, RAEB-2 refractory anemia with excess blast-2, BM bone marrow. aIn MDS cohort, karyotype findings included very good : –Y (n = 1); good: normal (n = 32), intermediate: +8 (n = 1); other (n = 1); poor: 3 abnormalities (n = 1), and very poor: >3 abnormalities (n = 1)
\